BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 36414547)

  • 1. Malignant peripheral nerve sheath tumor in children: A clinicopathologic and molecular study with parallels to the adult counterpart.
    Agaram NP; Wexler LH; Chi P; Antonescu CR
    Genes Chromosomes Cancer; 2023 Mar; 62(3):131-138. PubMed ID: 36414547
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beyond "Triton": Malignant Peripheral Nerve Sheath Tumors With Complete Heterologous Rhabdomyoblastic Differentiation Mimicking Spindle Cell Rhabdomyosarcoma.
    Hornick JL; Nielsen GP
    Am J Surg Pathol; 2019 Oct; 43(10):1323-1330. PubMed ID: 31107719
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Malignant peripheral nerve sheath tumor: a clinicopathological analysis].
    Peng W; Gong QX; Fan QH; Liu Y; Song GX; Wei YZ
    Zhonghua Bing Li Xue Za Zhi; 2023 Sep; 52(9):924-930. PubMed ID: 37670622
    [No Abstract]   [Full Text] [Related]  

  • 4. Loss of dimethylated H3K27 (H3K27me2) expression is not a specific marker of malignant peripheral nerve sheath tumor (MPNST): An immunohistochemical study of 137 cases, with emphasis on MPNST and melanocytic tumors.
    Thangaiah JJ; Westling BE; Roden AC; Giannini C; Tetzlaff M; Cho WC; Folpe AL
    Ann Diagn Pathol; 2022 Aug; 59():151967. PubMed ID: 35567887
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Clinicopathologic Study of Head and Neck Malignant Peripheral Nerve Sheath Tumors.
    Owosho AA; Estilo CL; Huryn JM; Chi P; Antonescu CR
    Head Neck Pathol; 2018 Jun; 12(2):151-159. PubMed ID: 28762137
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Malignant peripheral nerve sheath tumor (MPNST) and MPNST-like entities are defined by a specific DNA methylation profile in pediatric and juvenile population.
    Patrizi S; Miele E; Falcone L; Vallese S; Rossi S; Barresi S; Giovannoni I; Pedace L; Nardini C; Masier I; Abballe L; Cacchione A; Russo I; Di Giannatale A; Di Ruscio V; Salgado CM; Mastronuzzi A; Ciolfi A; Tartaglia M; Milano GM; Locatelli F; Alaggio R
    Clin Epigenetics; 2024 Jan; 16(1):9. PubMed ID: 38178234
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Confirmation of mutation landscape of NF1-associated malignant peripheral nerve sheath tumors.
    Sohier P; Luscan A; Lloyd A; Ashelford K; Laurendeau I; Briand-Suleau A; Vidaud D; Ortonne N; Pasmant E; Upadhyaya M
    Genes Chromosomes Cancer; 2017 May; 56(5):421-426. PubMed ID: 28124441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Methylation-based classification of benign and malignant peripheral nerve sheath tumors.
    Röhrich M; Koelsche C; Schrimpf D; Capper D; Sahm F; Kratz A; Reuss J; Hovestadt V; Jones DT; Bewerunge-Hudler M; Becker A; Weis J; Mawrin C; Mittelbronn M; Perry A; Mautner VF; Mechtersheimer G; Hartmann C; Okuducu AF; Arp M; Seiz-Rosenhagen M; Hänggi D; Heim S; Paulus W; Schittenhelm J; Ahmadi R; Herold-Mende C; Unterberg A; Pfister SM; von Deimling A; Reuss DE
    Acta Neuropathol; 2016 Jun; 131(6):877-87. PubMed ID: 26857854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low mutation burden and frequent loss of CDKN2A/B and SMARCA2, but not PRC2, define premalignant neurofibromatosis type 1-associated atypical neurofibromas.
    Pemov A; Hansen NF; Sindiri S; Patidar R; Higham CS; Dombi E; Miettinen MM; Fetsch P; Brems H; Chandrasekharappa SC; Jones K; Zhu B; Wei JS; ; ; Mullikin JC; Wallace MR; Khan J; Legius E; Widemann BC; Stewart DR
    Neuro Oncol; 2019 Aug; 21(8):981-992. PubMed ID: 30722027
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunohistochemical evaluation of H3K27 trimethylation in malignant peripheral nerve sheath tumors.
    Otsuka H; Kohashi K; Yoshimoto M; Ishihara S; Toda Y; Yamada Y; Yamamoto H; Nakashima Y; Oda Y
    Pathol Res Pract; 2018 Mar; 214(3):417-425. PubMed ID: 29482987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular evolution of a neurofibroma to malignant peripheral nerve sheath tumor (MPNST) in an NF1 patient: correlation between histopathological, clinical and molecular findings.
    Spurlock G; Knight SJ; Thomas N; Kiehl TR; Guha A; Upadhyaya M
    J Cancer Res Clin Oncol; 2010 Dec; 136(12):1869-80. PubMed ID: 20229272
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss of H3K27me3 Expression Is a Highly Sensitive Marker for Sporadic and Radiation-induced MPNST.
    Prieto-Granada CN; Wiesner T; Messina JL; Jungbluth AA; Chi P; Antonescu CR
    Am J Surg Pathol; 2016 Apr; 40(4):479-89. PubMed ID: 26645727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A neurogenic tumor containing a low-grade malignant peripheral nerve sheath tumor (MPNST) component with loss of p16 expression and homozygous deletion of CDKN2A/p16: a case report showing progression from a neurofibroma to a high-grade MPNST.
    Tajima S; Koda K
    Int J Clin Exp Pathol; 2015; 8(5):5113-20. PubMed ID: 26191206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patterns of recurrence and survival in sporadic, neurofibromatosis Type 1-associated, and radiation-associated malignant peripheral nerve sheath tumors.
    Watson KL; Al Sannaa GA; Kivlin CM; Ingram DR; Landers SM; Roland CL; Cormier JN; Hunt KK; Feig BW; Ashleigh Guadagnolo B; Bishop AJ; Wang WL; Slopis JM; McCutcheon IE; Lazar AJ; Torres KE
    J Neurosurg; 2017 Jan; 126(1):319-329. PubMed ID: 27035165
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loss of H3K27 tri-methylation is a diagnostic marker for malignant peripheral nerve sheath tumors and an indicator for an inferior survival.
    Cleven AH; Sannaa GA; Briaire-de Bruijn I; Ingram DR; van de Rijn M; Rubin BP; de Vries MW; Watson KL; Torres KE; Wang WL; van Duinen SG; Hogendoorn PC; Lazar AJ; Bovée JV
    Mod Pathol; 2016 Jun; 29(6):582-90. PubMed ID: 26990975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Whole Exome Sequencing Reveals the Order of Genetic Changes during Malignant Transformation and Metastasis in a Single Patient with NF1-plexiform Neurofibroma.
    Hirbe AC; Dahiya S; Miller CA; Li T; Fulton RS; Zhang X; McDonald S; DeSchryver K; Duncavage EJ; Walrath J; Reilly KM; Abel HJ; Pekmezci M; Perry A; Ley TJ; Gutmann DH
    Clin Cancer Res; 2015 Sep; 21(18):4201-11. PubMed ID: 25925892
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors.
    Lee W; Teckie S; Wiesner T; Ran L; Prieto Granada CN; Lin M; Zhu S; Cao Z; Liang Y; Sboner A; Tap WD; Fletcher JA; Huberman KH; Qin LX; Viale A; Singer S; Zheng D; Berger MF; Chen Y; Antonescu CR; Chi P
    Nat Genet; 2014 Nov; 46(11):1227-32. PubMed ID: 25240281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neurofibromatosis-associated malignant peripheral nerve sheath tumors in children have a worse prognosis: A nationwide cohort study.
    Martin E; Coert JH; Flucke UE; Slooff WM; van de Sande MAJ; van Noesel MM; Grünhagen DJ; Wijnen MHWA; Verhoef C
    Pediatr Blood Cancer; 2020 Apr; 67(4):e28138. PubMed ID: 31889416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic Pathology of Tumors of Peripheral Nerve.
    Belakhoua SM; Rodriguez FJ
    Neurosurgery; 2021 Feb; 88(3):443-456. PubMed ID: 33588442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical genomic profiling identifies TYK2 mutation and overexpression in patients with neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors.
    Hirbe AC; Kaushal M; Sharma MK; Dahiya S; Pekmezci M; Perry A; Gutmann DH
    Cancer; 2017 Apr; 123(7):1194-1201. PubMed ID: 27875628
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.